earnings
confidence high
sentiment positive
materiality 0.85
Halozyme Q3 revenue up 34% to $290M; raises full-year guidance on strong royalty growth
HALOZYME THERAPEUTICS, INC.
2024-Q3 EPS reported
$2.37
revenue$717,316,000
- Total revenue $290.1M (+34% YoY); royalty revenue $155.1M (+36% YoY).
- GAAP diluted EPS $1.05 (+72% YoY); Non-GAAP diluted EPS $1.27 (+69% YoY).
- 2024 guidance raised: revenue $970M-$1.02B, Adj. EBITDA $595M-$625M, Non-GAAP EPS $4.00-$4.20.
- argenx expanded ENHANZE deal (4 new targets) for $30M upfront; ViiV added another target.
- Cash and securities $666.3M, up from $336M at Dec 2023, driven by operations.